Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have signed a written consent form before any trial-related procedures begin
• People whose physical functioning is rated at 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activities)
• People who have been confirmed, through tissue or cell testing or through standard clinical diagnostic guidelines, to have liver cancer (hepatocellular carcinoma, or HCC)
• People whose liver cancer is classified as Barcelona Clinic Liver Cancer (BCLC) stage C (an advanced stage)
• People who have been newly diagnosed with liver cancer and have not yet received any treatment for it
• People whose liver function score (Child-Pugh score) is 7 or below
• People whose estimated life expectancy is more than 12 weeks
• People who have at least one tumour that can be measured using standard imaging guidelines
• People whose organs (such as kidneys and liver) and bone marrow are functioning well enough to meet the trial's requirements

Who may not be able to join:

• People who have been confirmed to have specific rare types of liver or bile duct cancer (fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, or cholangiocarcinoma)
• People who have a history of a condition where the liver fails to remove toxins from the blood (hepatic encephalopathy), or who have had a liver transplant
• People who have fluid build-up in the chest, abdomen, or around the heart that requires draining
• People with active hepatitis B or C infections above certain levels, or who test positive for both hepatitis B and hepatitis C markers at the same time
• People whose cancer has spread to the brain or spinal cord
• People who have had bleeding from swollen veins in the oesophagus or stomach in the past 6 months, or who have been found to have severe varicose veins in those areas within the past 3 months, or who are assessed by the doctor as being at high risk of such bleeding
• People who have had any life-threatening bleeding event in the past 3 months, including bleeding that required a blood transfusion, surgery, or ongoing medication
• People who have had a serious blood clot or blockage in an artery or vein in the past 6 months, such as a heart attack, stroke, pulmonary embolism, or deep vein thrombosis (confirm with trial site for full details on permitted exceptions)
• People who have tumour clots blocking major blood vessels leading to or from the liver, or a tumour clot in the large vein that carries blood to the heart
• People who have taken high-dose aspirin (over 325 mg/day for 10 or more days in a row) or certain other blood-thinning medications within 2 weeks before the first dose
• People with high blood pressure that cannot be controlled with medication, or who have a history of a severe high blood pressure crisis or related brain condition
• People who still have significant side effects from previous treatments that have not yet settled down to a mild or absent level
• People with significant heart failure symptoms, poorly controlled irregular heartbeat, a history of a certain inherited heart rhythm condition, or a specific abnormal heart rhythm reading found during screening
• People with serious problems affecting their blood's ability to clot, or who are currently receiving clot-dissolving treatment
• People with a history of a hole or tear in the digestive tract, bowel blockage, major bowel surgery, Crohn's disease, ulcerative colitis, or chronic diarrhoea in the past 6 months
• People who have received immune-suppressing medications within 4 weeks before the first dose (certain low-dose or topical exceptions may apply — confirm with trial site)
• People who have received a live vaccine within 4 weeks before the first dose, or who plan to receive one during the trial
• People who have had major surgery within 4 weeks before the first dose, or who have wounds, ulcers, or fractures that have not yet healed, or who have had minor surgical procedures (other than blood draws or IV line placement) within 7 days before the first dose
• People who have received local treatment directed at the liver cancer within 4 weeks before the first dose, or who have received certain traditional or immune-modulating medicines within 2 weeks before the first dose
• People with uncontrolled metabolic conditions, serious non-cancer organ diseases, or other health circumstances that the trial doctor considers unsuitable for participation

Important: Always verify eligibility with the trial site directly before applying.